J Clin Oncol 2021 Jan 20
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
Abstract
Purpose
This study investigates whether focal boosting of the macroscopic visible tumor with external beam radiotherapy increases biochemical disease-free survival (bDFS) in patients with localized prostate cancer.
Patients and methods
In the phase III, multicenter, randomized controlled Focal Lesion Ablative Microboost in Prostate Cancer trial, 571 patients with intermediate- and high-risk prostate cancer were enrolled between 2009 and 2015. Patients assigned to standard treatment received 77 Gy (fractions of 2.2 Gy) to the entire prostate. The focal boost arm received an additional simultaneous integrated focal boost up to 95 Gy (fractions up to 2.7 Gy) to the intraprostatic lesion visible on multiparametric magnetic resonance imaging. Organ at risk constraints were prioritized over the focal boost dose. The primary end point was 5-year bDFS. Secondary end points were disease-free survival (DFS), distant metastases-free survival, prostate cancer-specific survival, overall survival, toxicity, and health-related quality of life.
Results
Median follow-up was 72 months. Biochemical DFS was significantly higher in the focal boost compared with the standard arm (hazard ratio 0.45, 95% CI, 0.28 to 0.71, P < .001). At 5-year follow-up bDFS was 92% and 85%, respectively. We did not observe differences in prostate cancer-specific survival (P = .49) and overall survival (P = .50). The cumulative incidence of late genitourinary and GI toxicity grade ≥ 2 was 23% and 12% in the standard arm versus 28% and 13% in the focal boost arm, respectively. Both for late toxicity as health-related quality of life, differences were small and not statistically significant.
Conclusion
The addition of a focal boost to the intraprostatic lesion improved bDFS for patients with localized intermediate- and high-risk prostate cancer without impacting toxicity and quality of life. The Focal Lesion Ablative Microboost in Prostate Cancer study shows that a high focal boost strategy to improve tumor control while respecting organ at risk dose constraints is effective and safe.
Related Questions
What institutional recommendations guide the choice between brachytherapy and MR-linac-guided SBRT for locally advanced prostate cancer, given that no large trials have directly compared the two?
There is randomized data demonstrating the superiority of brachytherapy boost over EBRT alone mainly from the well-discussed ASCENDE-RT trial. To my knowledge, there is no such data for SBRT (whether alone or as a boost) in this patient population. So, I do not see how they can be considered equal o...
How would you optimally boost patients with high or very high risk prostate cancer receiving definitive radiotherapy in 2025?
Micro-boost is my preferred strategy for dose escalation. The FLAME trial demonstrated a bDFS benefit (Kerkmeijer et al., PMID 33471548). The secondary analysis demonstrated reduced regional+distant metastasis and reduced local recurrence, as well (Groen et al., PMID 34953603). These benefits were ...
As PARTIQoL was a negative study, what is the current role for proton therapy in the management of prostate cancer patients?
Thank you for the comprehensive answer Dr. @Dr. First Last! It is interesting you talk about integral dose - that almost rarely comes up from the patient in my experience. They have read and have been told that it IS less toxic (not that it may be). They are told that protons are better and the auth...
If using 26-fraction moderate hypofractionation, what dose do you use for the intraprostatic dominant nodule SIB?
The definition of a nominal prescription dose for a focal boost is a confusing topic as often times the coverage at a given prescription dose is outside the realm of what is usually considered a valid prescription dose (i.e., coverage at a requested prescription dose is < 95%), and a prior thread al...
How would you manage sarcomatoid carcinoma of the prostate with poorly differentiated adenocarcinoma that is not amenable to surgery?
There is data on this rare histologic variant, albeit limited, and often in these situations we try to extrapolate from analogous areas with more data.It is believed that the pathogenesis of these tumors, the epithelial and sarcomatoid components, arise from a single cell of origin, rather than sepa...
Do you still order mpMRI for staging of prostate cancer in addition to PET-PSMA?
Yes, I still think the prostate MRI adds valuable information for target delineation and local staging. This position is consistent with a recent poll of GU specialists where about 90% of respondents believed that a prostate MRI was still necessary after a PET/CT (Gillessen et al., PMID 35450732).My...
Is there an SIB boost regimen for a dominant prostate lesion for 60 Gy/20 fx to the whole prostate?
There are no phase III data providing guidance on the "isotoxic" boost dose for a 20-fraction, hypofractionated prostate treatment similar to the experimental arm in FLAME (Kerkmeijer et al., PMID 33471548), but there are two prospective studies of which I am aware, DELINEATE and ARO2020-01, which d...
Would you offer focal prostate boost per FLAME protocol for GTV defined by PET alone without MRI?
I think there are two questions here: Can you use PSMA PET to define the boost target? Yes (with a little bit of caution). There have been several reports on the safety/feasibility of PSMA-based focal boost. Note, though, that FLAME was based on MRI, and we can expect that the PET-defined lesion may...
Would you add ADT to EBRT for favorable intermediate risk patients with T1c prostate cancer by DRE and bilateral prostatic lobe involvement by MRI?
Let's break down the question: If the patient has favorable intermediate risk disease, but cT1c by DRE, then he must have either: Grade group 2 (Gleason 3+4), PSA <10, and percent positive cores <50%; or Grade group 1 (Gleason 3+3), PSA 10-20, and percent positive cores <50% For scenario 1: Havi...
Would you offer prostate SBRT to a patient who cannot have an MRI?
Agree with Dr. @Dr. First Last, that yes, in a global sense, it's feasible. My only caveat - we routinely use the MRI to help delineate the urethra, as our institutional prostate SBRT dose is 40 Gy in 5 fractions to PTV, with hard constraint of limiting DMax of urethra to < 42 Gy. I routinely plan t...
Do you perform an MRI after SpaceOAR Vue placement if you already have a pre-procedural MRI and are not doing a FLAME style boost?
I do, yes. I also obtain MRI for planning when there is no hydrogel spacer (as did many before me when no one was using spacers).The apex and base are better demonstrated on MRI. This paper by McLaughlin et al., PMID 19515511 shows examples of common errors on CT-only contours.I do focal RT boost on...
How does a diffusely positive PSMA in the prostate affect treatment planning in a patient with MRI and biopsy showing only one area of disease?
There are three parts to my answer: First, mild to moderate PSMA uptake can be seen in benign conditions, including BPH and prostatitis (e.g., reviewed by Satapathy et al., PMID 32755196). Second, I don't see how the discrepancy between PSMA PET and MRI/biopsy would affect radiation treatment planni...
What references do you use for multi-parametric MRI delineation of the GTV in prostate cancer for prostate nodule?
In FLAME, the boost volume was the GTV on mpMRI as judged by the treating physician without any formal contouring guidelines (Kerkmeijer et al., PMID 33471548). There were differences in MRI protocols and physician judgement resulting in significant differences in tumor volumes between centers (van ...
Would you consider modifying the dose for focal prostate boost to other fractionation schedules?
DELINEATE was a phase II trial from the NHS which was designed to evaluate the toxicity of a simultaneous integrated boost (SIB) to the mpMRI-defined dominant intraprostatic nodule (DIL) for two fractionation schedules: conventional fractionation (cohort A) and hypofractionation in 20 fractions (coh...
Would you consider a focal prostate boost per FLAME trial with treatment of the pelvis?
The FLAME III trial evaluated a focal dose boost to the prostate tumor if it could be achieved without exceeding dose constraints. By extension, if you can achieve escalated dose to the tumor without meaningfully affecting your plan quality from an OAR perspective, I think this is a very reasonable ...
Based on the recent guidelines, should prostate SBRT dose be no higher than 3625 cGy in 5 fractions?
We have delivered prostate SBRT in high volume using 3,800 cGy/4 fx since 2006. The UCSF group has also used this schedule in a large number of patients for a similar time frame. For over a decade prior to that, the exact same dose regimen was used with HDR brachytherapy and published as "safe and e...
What is your approach to a patient with prostate cancer with suspicion of rectal wall invasion but otherwise localized disease?
My approach in a prostate cancer patient with "suspicious" rectal involvement is to verify, in fact, if he has actual rectal involvement, or not and NOT "suspicious" involvement. I guess my point is that I WOULD BE VERY hesitant to start RT intervention without verifying if the patient had rectal in...